Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.
Clover Health Investments, Corp.'s CEO for Medicare Advantage reported automatic share withholding transactions related to restricted stock unit vesting.
On December 14, 2025 and December 15, 2025, 12,567 and 8,691 shares of Class A Common Stock, respectively, were withheld at $2.7 per share to cover tax obligations when 6.25% quarterly tranches of time-based RSU grants from March 14, 2022 and September 16, 2022 vested. After these transactions, the officer directly beneficially owns 2,772,153 shares of Class A Common Stock, and the remaining RSUs continue to vest quarterly in 6.25% installments through March 14, 2026 and September 15, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider share withholding related to restricted stock vesting. On December 14, 2025, an officer serving as CEO, Counterpart Health had 98,411 shares of Class A common stock automatically withheld at $2.7 per share to cover tax obligations when a portion of previously granted restricted stock units vested.
After this transaction, the reporting person beneficially owned 1,051,674 Class A shares directly and 1,610,482 shares indirectly through a trust. The withheld shares correspond to 6.25% of the original time-based RSU grant made on March 14, 2022, which continues to vest in equal 6.25% quarterly installments through March 14, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider equity transaction by an officer serving as General Counsel & Secretary. On December 15, 2025, 6,404 shares of Class A common stock were withheld to cover tax obligations triggered by the vesting of time-based restricted stock units (RSUs).
The withheld shares correspond to 6.25% of the original RSU grant made on September 15, 2022. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments, with a final vesting date on September 15, 2026, subject to the reporting person’s continued service. Following this tax-withholding event, the reporting person beneficially owns 1,222,365 Class A shares directly.
Clover Health Investments Corp. insider tax withholding transaction
A Clover Health Investments Corp. officer, serving as General Counsel and Secretary, reported an automatic share withholding related to restricted stock units. On November 14, 2025, 7,459 shares of Class A common stock were withheld at a price of $2.47 per share to cover tax obligations triggered by the vesting of time-based restricted stock units granted on February 14, 2022. After this transaction, the reporting person beneficially owned 1,228,769 shares of Class A common stock. The underlying restricted stock units vest in quarterly installments of 6.25%, with the final vesting date scheduled for February 14, 2026, conditioned on continued service.
Clover Health (CLOV) reported an insider Form 4 for CEO and Director Andrew Toy. On 11/08/2025, 85,535 shares of Class A common stock were withheld at $2.67 per share under transaction code F, reflecting automatic share withholding to cover taxes upon RSU vesting.
The vesting represented 6.25% of RSUs granted on 08/08/2022. Following the transaction, Toy beneficially owns 9,837,447 shares directly. The remaining RSUs vest quarterly in equal 6.25% installments through 08/08/2026, subject to continued service.
Clover Health Investments (CLOV) furnished a Regulation FD update, publishing written responses to select shareholder questions tied to its third quarter 2025 earnings announcement. The Supplemental Shareholder Q&A is included as Exhibit 99.1 and is also available on the company’s investor relations website. The company states this information is furnished, not filed, and is not incorporated by reference unless specifically noted.
Clover Health Investments (CLOV) filed its Q3 2025 10‑Q, reporting higher revenue but a wider loss. Total revenues were $496.7 million for the quarter, up from $331.0 million a year ago, driven primarily by higher premiums earned. Net loss from continuing operations was $24.4 million, compared with $8.8 million in the prior-year quarter, as net medical claims and operating costs increased with membership activity.
For the nine months ended September 30, 2025, revenue reached $1.44 billion and net loss from continuing operations was $36.2 million. Cash and cash equivalents were $190.1 million as of September 30, 2025. Unpaid claims declined to $140.5 million from $156.4 million at year‑end, reflecting faster claim processing. Stockholders’ equity was $340.9 million. The company also recognized fair value gains tied to a remeasured private equity investment and realized gains on warrant liquidations, recorded in other income.
Class A shares outstanding were 421.8 million and Class B 92.4 million as of September 30, 2025, with treasury stock increasing due to repurchases and tax withholdings on equity awards.
Clover Health Investments (CLOV): insider transaction disclosed. Officer Jamie L. Reynoso (CEO, Medicare Advantage) sold 30,385 shares of Class A common stock at a weighted average price of $3.58 on November 4, 2025, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owned 2,793,411 shares directly. The sale was executed in multiple trades at prices ranging from $3.49 to $3.67, and the reporting person undertakes to provide detailed trade breakdowns upon request.
Clover Health Investments (CLOV) disclosed a Form 4 for an officer (CEO of Home Care) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, the company automatically withheld 86,610 and 25,081 Class A shares at $3.53 per share to cover taxes as restricted stock units vested.
The filing notes these were tied to the final 50% of earned performance-based RSUs from an award dated October 31, 2023, and the final 12.5% of another RSU tranche vesting the same day. Following these transactions, the reporting person directly beneficially owned 2,228,583 Class A shares.